E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
This trial will be conducted in a population of preterm infants who are at high risk of developing BPD. It will not only enroll infants requiring mechanical ventilation, but also infants on nasal ventilation or continuous positive airway pressure (CPAP). The latter group does not appear to be significantly affected by lung disease shortly after birth; however, it is at high risk of developing the "new BPD". |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10006475 |
E.1.2 | Term | Bronchopulmonary Dysplasia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether inhalation of Budesonide within 12 hours of life improves survival and precludes BPD at 36 weeks GA in infants born between 23 and 27 weeks GA. |
|
E.2.2 | Secondary objectives of the trial |
1) To determine whether prophylactic inhalation of budesonide affects neurodevelopment at a corrected age of 18-22 months in preterm infants. 2) To determine whether inhalation of corticosteroids is associated with: - Adverse treatment effects, - Alters mortality at 36 weeks GA, - BPD incidence at 36 weeks GA, - The duration of positive pressure respiratory support or supplemental oxygen. 3) The severity of BPD will be determined according to three different definitions in an exploratory analysis. 4) Data on the pharmacokinetics and pharmacogenetics of inhaled corticosteroids will be collected and a substudy on the genetic predisposition to BPD will be performed in conjunction with the controlled clinical study. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
1) Pharmacokinetric / Pharmacodynamic / Pharmacogenetic substudy:
Objective: To perform PK / PD analyses and to determine whether certain individual genetic aspects account for individualised drug metabolism.
Version : NEUROSIS; Proposal N°.: 223060; Actual drafting date: 02.09.2008
2) Genetic background of BPD substudy:
Objective: To determine whether certain candidate genes are associated with the development of BPD.
Version : NEUROSIS; Proposal N°.: 223060; Actual drafting date: 02.09.2008 |
|
E.3 | Principal inclusion criteria |
A gestational age of 23 0/7- 27 6/7 weeks, a postnatal age a postnatal age < 12 hours, the necessity for any form of positive pressure support (mechanical or nasal ventilation or CPAP), singleton or second born in case of multiple pregnancy and parental consent for participation. |
|
E.4 | Principal exclusion criteria |
A clinical decision not to administer therapies (infant not considered viable), dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment including all congenital pulmonary malformations, and known or suspected congenital heart disease (not including a persistent ductus arteriosus and/or an atrial septum defect).
The clinical assessment of dysmorphic features, congenital malformations, suspected congenital heart disease and the decision to exclude an infant for the aforementioned reasons will be left to the discretion of the attending physician.
Other exclusion criteria are: nosocomial pulmonary viral infections and hypersensitivity to any component of inhaled budesonide (budesonide itself, glycerol, ethanol, HFA-134A (norflurane)).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The parameter for the confirmatory analysis of efficacy will be the incidence of primary endpoints. A primary endpoint is defined as the occurrence of any of the following events during the first 36 weeks gestational age : (1) Death for any reason by the end of week 36 gestational age; (2) BPD according to the physiological definition, diagnosed at 36 weeks +/-1 day gestational age.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 0 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |